New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:03 EDTBAXBaxter presents data from AHEAD study
Baxter International presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD study, a four-year outcomes registry of hemophilia A patients treated with ADVATE. These data were presented during the European Association for Haemophilia and Allied Disorders meeting in Brussels, Belgium. These real-world data, which support the clinical experience of prophylaxis treatment with ADVATE, found that the majority of patients (55.3%) on prophylaxis had fewer than two bleeding episodes per year, with a median annual bleed rate of 1.1. Of these patients, 51 percent experienced no bleeds during one year of treatment.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
09:15 EDTBAXBaxter says 'feels good' about guidance
Subscribe for More Information
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Subscribe for More Information
07:05 EDTBAXBaxter sees Q3 EPS before special items $1.28-$1.32, consensus $1.32
The company said, "For Q3, the company expects sales growth of approximately 12%-13%, excluding the impact of foreign currency. TheQ3 earnings guidance excludes approximately 7c per diluted share of projected intangible asset amortization expense."
07:04 EDTBAXBaxter narrows FY14 adjusted EPS view to $5.10-$5.20, consensus $5.15
Subscribe for More Information
07:02 EDTBAXBaxter reports Q2 adjusted EPS $1.26, consensus $1.22
Reports Q2 revenue $4.26B, consensus $4.12B.
07:01 EDTBAXBaxter confirms FY14 outlook
Subscribe for More Information
July 16, 2014
15:27 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use